GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhenomeX Inc (NAS:CELL) » Definitions » Debt-to-EBITDA

PhenomeX (PhenomeX) Debt-to-EBITDA : -0.17 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is PhenomeX Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PhenomeX's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $5.02 Mil. PhenomeX's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was $23.95 Mil. PhenomeX's annualized EBITDA for the quarter that ended in Jun. 2023 was $-172.94 Mil. PhenomeX's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 was -0.17.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PhenomeX's Debt-to-EBITDA or its related term are showing as below:

CELL' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.79   Med: -1.14   Max: -0.27
Current: -0.27

During the past 5 years, the highest Debt-to-EBITDA Ratio of PhenomeX was -0.27. The lowest was -2.79. And the median was -1.14.

CELL's Debt-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 1.36 vs CELL: -0.27

PhenomeX Debt-to-EBITDA Historical Data

The historical data trend for PhenomeX's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhenomeX Debt-to-EBITDA Chart

PhenomeX Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22
Debt-to-EBITDA
-1.17 -2.79 -1.14 -0.75 -0.54

PhenomeX Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.63 -0.44 -1.24 -0.17

Competitive Comparison of PhenomeX's Debt-to-EBITDA

For the Biotechnology subindustry, PhenomeX's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PhenomeX's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PhenomeX's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PhenomeX's Debt-to-EBITDA falls into.



PhenomeX Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PhenomeX's Debt-to-EBITDA for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(8.257 + 37.586) / -84.906
=-0.54

PhenomeX's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(5.018 + 23.95) / -172.944
=-0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2023) EBITDA data.


PhenomeX  (NAS:CELL) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PhenomeX Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PhenomeX's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PhenomeX (PhenomeX) Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 320, Emeryville, CA, USA, 94608
PhenomeX Inc is a functional cell biology company that provides live cell biology research tools which deliver deep insights into cellular function and new perspectives on phenomes.
Executives
Siddhartha Kadia director, officer: Chief Executive Officer 7475 LUSK BOULEVARD, SAN DIEGO CA 92121
Mehul Joshi officer: Chief Financial Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Peter Silvester director C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
John R Chiminski director C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Bird Mergersub Corp 10 percent owner 40 MANNING ROAD, BILLERICA MA 01821
Bruker Corp 10 percent owner 40 MANNING RD, BILLERICA MA 01821
James Paul Mcclaskey officer: SVP, Chief Accounting Officer C/O BERKELEY LIGHTS, INC., C/O BERKELEY LIGHTS, INC., EMERYVILLE CA 94608
Scott David Chaplin officer: Chief Legal Officer 3101 WILSON BOULEVARD, SUITE 700, ARLINGTON VA 22201
Eric Hobbs director, officer: Chief Executive Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
James Rothman director 135 EAST 83RD STREET, APT. 15C, NEW YORK NY 10028
Gregory T Lucier director C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Keith Breinlinger officer: Chief Technical Officer C/O BERKELEY LIGHTS, INC., 5858 HORTON STREET, SUITE 320, EMERYVILLE CA 94608
Igor Y Khandros director, 10 percent owner 25 HACIENDAS ROAD, ORINDA CA 94563
Stuart L Merkadeau officer: General Counsel 7005 SOUTHFRONT ROAD, LIVERMORE CA 94551